Adherence of SARS-CoV-2 Seroepidemiologic Studies to the ROSES-S Reporting Guideline During the COVID-19 Pandemic

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-07-25 DOI:10.1111/irv.13283

Brianna Cheng, Emma Loeschnik, Anabel Selemon, Reza Hosseini, Jane Yuan, Harriet Ware, Xiaomeng Ma, Christian Cao, Isabel Bergeri, Lorenzo Subissi, Hannah C. Lewis, Tyler Williamson, Paul Ronksley, Rahul K. Arora, Mairead Whelan, Niklas Bobrovitz

{"title":"Adherence of SARS-CoV-2 Seroepidemiologic Studies to the ROSES-S Reporting Guideline During the COVID-19 Pandemic","authors":"Brianna Cheng, Emma Loeschnik, Anabel Selemon, Reza Hosseini, Jane Yuan, Harriet Ware, Xiaomeng Ma, Christian Cao, Isabel Bergeri, Lorenzo Subissi, Hannah C. Lewis, Tyler Williamson, Paul Ronksley, Rahul K. Arora, Mairead Whelan, Niklas Bobrovitz","doi":"10.1111/irv.13283","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Complete reporting of seroepidemiologic studies is critical to their utility in evidence synthesis and public health decision making. The Reporting of Seroepidemiologic studies—SARS-CoV-2 (ROSES-S) guideline is a checklist that aims to improve reporting in SARS-CoV-2 seroepidemiologic studies. Adherence to the ROSES-S guideline has not yet been evaluated.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This study aims to evaluate the completeness of SARS-CoV-2 seroepidemiologic study reporting by the ROSES-S guideline during the COVID-19 pandemic, determine whether guideline publication was associated with reporting completeness, and identify study characteristics associated with reporting completeness.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A random sample from the SeroTracker living systematic review database was evaluated. For each reporting item in the guideline, the percentage of studies that were adherent was calculated, as well as median and interquartile range (IQR) adherence across all items and by item domain. Beta regression analyses were used to evaluate predictors of adherence to ROSES-S.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>One hundred and ninety-nine studies were analyzed. Median adherence was 48.1% (IQR 40.0%–55.2%) per study, with overall adherence ranging from 8.8% to 72.7%. The laboratory methods domain had the lowest median adherence (33.3% [IQR 25.0%–41.7%]). The discussion domain had the highest median adherence (75.0% [IQR 50.0%–100.0%]). Reporting adherence to ROSES-S before and after guideline publication did not significantly change. Publication source (<i>p</i> < 0.001), study risk of bias (<i>p</i> = 0.001), and sampling method (<i>p</i> = 0.004) were significantly associated with adherence.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Completeness of reporting in SARS-CoV-2 seroepidemiologic studies was suboptimal. Publication of the ROSES-S guideline was not associated with changes in reporting practices. Authors should improve adherence to the ROSES-S guideline with support from stakeholders.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 7","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272216/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13283","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Complete reporting of seroepidemiologic studies is critical to their utility in evidence synthesis and public health decision making. The Reporting of Seroepidemiologic studies—SARS-CoV-2 (ROSES-S) guideline is a checklist that aims to improve reporting in SARS-CoV-2 seroepidemiologic studies. Adherence to the ROSES-S guideline has not yet been evaluated.

Objectives

This study aims to evaluate the completeness of SARS-CoV-2 seroepidemiologic study reporting by the ROSES-S guideline during the COVID-19 pandemic, determine whether guideline publication was associated with reporting completeness, and identify study characteristics associated with reporting completeness.

Methods

A random sample from the SeroTracker living systematic review database was evaluated. For each reporting item in the guideline, the percentage of studies that were adherent was calculated, as well as median and interquartile range (IQR) adherence across all items and by item domain. Beta regression analyses were used to evaluate predictors of adherence to ROSES-S.

Results

One hundred and ninety-nine studies were analyzed. Median adherence was 48.1% (IQR 40.0%–55.2%) per study, with overall adherence ranging from 8.8% to 72.7%. The laboratory methods domain had the lowest median adherence (33.3% [IQR 25.0%–41.7%]). The discussion domain had the highest median adherence (75.0% [IQR 50.0%–100.0%]). Reporting adherence to ROSES-S before and after guideline publication did not significantly change. Publication source (p < 0.001), study risk of bias (p = 0.001), and sampling method (p = 0.004) were significantly associated with adherence.

Conclusions

Completeness of reporting in SARS-CoV-2 seroepidemiologic studies was suboptimal. Publication of the ROSES-S guideline was not associated with changes in reporting practices. Authors should improve adherence to the ROSES-S guideline with support from stakeholders.

Abstract Image

查看原文本刊更多论文

在 COVID-19 大流行期间，SARS-CoV-2 血清流行病学研究是否遵守 ROSES-S 报告指南。

背景：血清流行病学研究的完整报告对其在证据综合和公共卫生决策中的作用至关重要。血清流行病学研究报告-SARS-CoV-2（ROSES-S）指南是一份旨在改进 SARS-CoV-2 血清流行病学研究报告的核对表。目前尚未对 ROSES-S 指南的遵守情况进行评估：本研究旨在评估 COVID-19 大流行期间按照 ROSES-S 指南进行 SARS-CoV-2 血清流行病学研究报告的完整性，确定指南的发布是否与报告完整性相关，并识别与报告完整性相关的研究特征：从 SeroTracker 活体系统综述数据库中随机抽取样本进行评估。针对指南中的每个报告项目，计算了遵守指南的研究百分比，以及所有项目和各项目领域遵守指南的中位数和四分位数区间（IQR）。贝塔回归分析用于评估ROSES-S遵守情况的预测因素：结果：共分析了 199 项研究。每项研究的坚持率中位数为 48.1%（IQR 40.0%-55.2%），总体坚持率从 8.8% 到 72.7% 不等。实验室方法领域的坚持率中位数最低（33.3% [IQR 25.0%-41.7%] ）。讨论领域的坚持率中位数最高（75.0% [IQR50.0%-100.0%]）。在指南发布前后，报告对 ROSES-S 的遵守情况没有明显变化。发表来源（P 结论：SARS 报告的完整性SARS-CoV-2血清流行病学研究报告的完整性不够理想。ROSES-S 指南的发布与报告方法的改变无关。作者应在利益相关者的支持下更好地遵守 ROSES-S 指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.